Zotefoams H1 2026: The TOLL Stock That Doesn't Look Like One

Do you know what scares me more than the risks of owning stocks? Not owning enough of the right ones — companies that provide what the economy cannot function without, at prices they control, with dividends that compound through full cycles.

Zotefoams plc (LON: ZTF) is one of those companies. If you haven't heard of it, that's part of the point. It's a £226 million market-cap specialty materials manufacturer that makes supercritical foams — lightweight, fire-resistant, high-performance materials used in aircraft interiors, EV battery casings, premium footwear midsoles, and aerospace insulation. The global market for supercritical foaming materials is roughly $1.25 billion today, projected to reach $2.5 billion by 2034 at an 8.7% compound annual growth rate. Zotefoams is among the few players with proprietary autoclave technology and a century of accumulated technical data.

The company just reported H1 2026 results on August 4th. The numbers are strong. The strategic pivot is clearer than ever. And the stock still looks like the kind of out-of-favor quality compounder that belongs in the income-growth sleeve.

What the H1 2026 Results Actually Show

Revenue rose 23% year-over-year to £95.2 million. Adjusted operating profit climbed 34% to £16.3 million, with the adjusted operating margin expanding 130 basis points to 17.1%. Adjusted EPS rose 29% to £0.257.

Those are the headline figures. The story underneath them is far more important.

Organic growth was 4% (6% at constant currency). The rest of the revenue increase came from the OKC acquisition — a Spanish technical foam producer that Zotefoams acquired in November 2025. OKC contributed just under £15 million in its first full half, came in ahead of plan, and was immediately earnings-accretive. That's not typical for add-ons in this sector. It tells you the integration playbook is working and there's cross-selling optionality between the two operations.

Non-footwear is now the engine. Transport & Smart Technologies revenue surged 76%, making it the company's largest vertical. Construction & Other Industrial grew 41%. These are the real-economy, mission-critical applications — aerospace seating, EV battery casings, high-performance insulation. This is the pivot management has been describing for years, and it's finally showing up in the numbers.

Footwear is normalizing, as warned. Consumer & Lifestyle revenue fell 19% after exceptional strength in H2 2024 and 2025. EMEA footwear specifically dropped 23%. Management framed this transparently in advance. This is a planned transition, not a structural collapse. The company is shifting footwear production from the UK to Vietnam and moving from traditional foam shapes to 3D preforms. The transition hurts revenue in the near term. But it's a cost structure improvement that will benefit margins once Vietnam reaches real production, targeted for June 2027.

North America is the dark horse. Revenue up 29%, with operating profit nearly tripling to £3.3 million. The North America margin jumped 930 basis points to 17.6%. Management stated that U.S. revenues could roughly double to about $100 million without major new investment, supported by existing capacity at their Walton, Kentucky and Tulsa, Oklahoma facilities. That is a growth runway most small-cap specialty manufacturers don't have.

Pricing Power: The Ultimate Test

This is the single filter that eliminates most dividend candidates. Can Zotefoams raise prices without losing customers?

The answer is yes, and the structural reasons are worth unpacking. Supercritical foam technology requires high-pressure reactors, precise temperature regulation, and years of proprietary formulation work. Entry barriers are steep — capital-intensive, technically complex, and protected by accumulated R&D that competitors can't shortcut. Zotefoams' ZOTEK® foam is positioned as the world's lightest closed-cell crosslinked high-performance foam with outstanding fire, smoke, and toxicity properties. In aerospace, where flight certification can take years, once a material is approved, it's not being replaced by a cheaper alternative. That's pricing power built on regulatory lock-in and technical performance.

The company's ZoteLabs AI platform — leveraging over 2.1 million technical files and millions of academic papers — accelerates material innovation cycles. This isn't a marketing gimmick. In a specialty materials business, the speed at which you can develop custom formulations for a customer's exact specification is a competitive weapon. It shortens development time, deepens customer relationships, and creates another moat layer.

The Balance Sheet Check

Net debt increased to £39.1 million from £31.5 million at year-end, driven by OKC deferred consideration payments, strategic CapEx, and working capital builds. The leverage ratio remains below 1.0x, which is conservative. A new £90 million multi-currency revolving credit facility provides £50 million in liquidity headroom.

Working capital increased by £14 million, roughly half tied to inventory builds for supply security and the Vietnam transition. Management expects elevated working capital to persist through 2026 and into 2027. Cash flow from operations dropped to £8.2 million from £15.8 million in H1 2025 — but that decline is investment-driven, not earnings-driven. The company is spending to build the future business.

From a dividend safety standpoint, the balance sheet passes. Low leverage, strong liquidity, and a credit facility that would absorb a significant adverse shock. The dividend isn't at risk.

The Dividend Growth Story

The interim dividend was proposed at £0.0263 per share, a 5% increase. The final dividend for FY2025 was £0.0535, up from £0.051 the prior year. That's consistent dividend growth, not a dramatic hike, but the trajectory is what matters.

I don't think investors are being paid to chase the highest current yield. The better setup is a company that can turn a modest yield into years of dividend growth. At a £420 share price, the forward yield is around 1.7%. That's not a income anchor. It's a compounder. The equity yield curve sweet spot sits between 2-4% yields with 8-15% dividend growth. Zotefoams sits below that yield range today, but the earnings growth trajectory — 29% EPS growth in H1, margin expansion, and the non-footwear pivot — suggests the dividend can grow at a faster clip than the yield alone implies.

The Roadmap: Where the Value Is Created

Management's medium-term targets are explicit: revenue above £230 million and operating profit above £40 million by FY2029, on an organic basis excluding future acquisitions. Current full-year 2025 revenue was £158.5 million. Getting from there to £230 million requires roughly 8.5% compound annual growth over three years, which is aggressive but not absurd given the non-footwear acceleration and the North America runway.

The UK Croydon restructuring proposal targets £4 million in annualized savings with a payback of less than one year, affecting more than 100 roles. These are proposals, not final decisions, but the direction is clear: shift UK operations toward materials innovation and non-footwear applications while moving commodity footwear production to lower-cost locations. That's the kind of operational discipline that compounds margins.

The Risks You Should Acknowledge

2027 will be a transition year. Management was direct about this. Footwear revenue is expected to remain lower through H2 2026 and into 2027 as production shifts to Vietnam. Working capital stays elevated. The Vietnam ramp carries execution risk — autoclaves are on site, injection molding machines delivered, but real production doesn't start until mid-2027. Management described 2027 as a year for modest profit progression, with stronger value creation expected from 2028 onward.

Raw material and freight cost inflation is a perpetual threat, partially mitigated by surcharge mechanisms. The company's balance sheet can absorb the shock, but margin volatility during cost spikes is real.

What It Means From a Risk/Reward Perspective

Zotefoams trades at roughly 10 times earnings on a £226 million market cap. The PEG ratio (price-to-earnings-growth) sits around 0.66, well below 1.0. For context, specialty chemical companies with comparable margin profiles and growth trajectories typically trade at 14-18x earnings. This stock is priced as if the footwear normalization is a structural problem rather than a transition period.

I believe that's the market's misread. The footwear decline is real but temporary. The non-footwear acceleration is real and structural. The North America optionality is real and underpriced. The technology moat is real and widening as aerospace, EV, and space applications compound demand.

This is not a stock I would treat as a yield shortcut. It belongs in the income-growth sleeve because the balance sheet, pricing power, and payout profile support compounding through a full cycle. From an income and risk/reward point of view, the appeal is a durable payout, a reasonable valuation relative to the growth trajectory, and enough structural tailwind to protect purchasing power even if inflation runs above traditional targets.

The concentrated investor who understands the business, the transition risk, and the three-to-five-year compounding path could find a meaningful opportunity here. The rest of the market is focused on FANG and quarterly GDP prints. Meanwhile, a small-cap materials specialist with 76% growth in aerospace and EV foams, a sub-1.0x leverage ratio, and a growing dividend is trading at 10 times earnings.

I don't need the market to fall for this setup to make sense. I just need the non-footwear growth to continue, Vietnam to ramp on plan, and the Croydon optimization to deliver. That's execution risk, not thesis risk. And from an income and risk/reward point of view, that's a bet I'd take.